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MCL1 is the predominant BCL2 family member expressed in primary AML samples. (A) Gene expression profiles were analyzed in 111 de novo 
AML samples, and high MCL1 expression was observed in all AML samples. Error bars represent mean ± SD. (B) MCL1, but not BCL2 and 
BCL-XL, were highly expressed in all AML subtypes. Expression levels of MCL1, BCL2, and BCL-XL were analyzed in AML samples of different 
French, American, and British (FAB) classification subtypes (M0–M7) and in cells from normal donors (sorted CD34+ cells, promyelocytes [Pro], 
and PMNs). Each data point represents 1 sample (either patient or sorted normal cells). (C) Elevated MCL1 expression was seen in almost all 
AML samples. Western blots of AML cells from newly diagnosed AML patients. Lanes 1–6, AML samples; lane 7, chronic myeloid leukemia 
sample; lane 8, K562 cell line; lane 9, normal human bone marrow mononuclear cell control.
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Elevated Mcl1 expression in myeloid leukemia cells from Myc-induced 

























































Elevated Mcl1 expression in myeloid leukemia cells from 
Myc-induced AML mice. (A) Western blot of protein lysates 
prepared from unfractionated bone marrow, spleen (Sp), 
and lymph node cells isolated from leukemic mice trans-
planted with MSCV-Myc (Myc), MSCV-Myc-Ires-Bcl2 
(MIB), or vector alone (GFP). (B) Western blot of sorted 
Gr-1+ myeloid (G) and B220+ B-lymphoid (B) cells and cells 
sorted by GFP expression from MSCV-Myc– or GFP-trans-
planted mice. Cells were harvested from moribund leuke-
mic mice, typically 4–6 weeks after transplantation, and 
from age-matched control mice. Representative blots from 
3 independent experiments are shown.
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Myc activation does not directly alter Mcl1 expression. (A) Elevated Myc target gene ODC expression upon Myc activation in 3T3 cells. 
RT-PCR was performed from RNA collected 0, 2, 4, and 6 hours after 4-OH tamoxifen treatment of MycER-transduced 3T3 cells (lanes 1–4, 
respectively) and GFP-transduced cells (0 and 6 hours; lanes 5 and 6, respectively). (B) Mcl1 expression was not changed in transduced 
BaF3 cells treated with ethanol (E) or with 4-OH tamoxifen dissolved in ethanol for the indicated times. SV40-transduced mouse embryonic 
fibroblasts (MEFs) were used as an Mcl1-positive control. (C) Mcl1 expression was not changed in transduced 3T3 cells treated for 24 hours 
with either 4-OH tamoxifen or ethanol. Myc-transduced 3T3 cells were used as a positive control. (D) Elevated Mcl1 expression in bone mar-
row cells after 7 days of Myc induction along with Gr-1+ cell expansion in bone marrow. Protein lysates were prepared from the mice treated 
with DMSO for 7 days (D7) or tamoxifen for 1 or 7days (T1 and T7, respectively). SV40-transduced mouse embryonic fibroblasts and bone 
marrow cells of Myc-induced leukemic mice were used as positive controls. Lanes were run on the same gel but were noncontiguous (white 
lines). (E) Tamoxifen treatment resulted in relative depletion of B220+ lymphoid cells with concurrent expansion of Gr-1+ myleoid cells in bone 
marrow (blue, Gr-1+; red, B220+). FSC, forward scatter; SSC, side scatter. Cells were gated for GFP, and the percentages of Gr-1+ and B220+ 
events are shown at right. Data are mean ± SD.
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Myc confers self-renewal ability to committed myeloid progenitor cells. 
As Myc induction did not increase the percentage and absolute 
Figure 4
HSC and progenitor populations were not 
expanded in Myc-induced leukemic mice. 
(A) HSCs (KSL) were decreased, as was 
the total progenitor pool (Kit+Sca–Lin–), after 
MycER induction for 7 days. CD34+FCγ– 
CMPs were comparable between tamoxi-
fen and DMSO treatment groups, a relative 
increase of CD34+FCγ+ GMPs was seen in 
MycER mice treated with tamoxifen, but 
also in control mice, and CD34–FCγ– MEPs 
were reduced after Myc induction. Repre-
sentative flow cytometry plots are shown 
from mice transplanted with MSCV-MycER 
(n = 3) or MSCV-GFP (n = 3). Numbers 
within dot plots represent the percentage of 
events within the respective gates. (B) Fre-
quencies of HSCs and progenitors in bone 
marrow of MycER mice. Absolute stem and 
progenitor cell numbers also decreased 
upon Myc induction (not shown). (C) Sorted 
KSL cells, a progenitor cell pool (Kit+Sca–
Lin–), and lineage-committed cells (Kit+Lin+) 
were transduced with Myc or GFP vector 
alone and plated in methylcellulose media 
in the absence or presence of cytokines. 
Myc induction increased cytokine-depen-
dent progenitor colonies that failed to 
self renew. Myc also induced replatable 
cytokine-independent colony formation, 
and, surprisingly, Kit+Lin+ cell–derived colo-
nies increased dramatically after third plat-
ing. Vector-transduced cells gave rise only 
to rare, non–self-renewing colonies (not 
shown). Kit–Lin+ cells were sorted but were 
substantially dead (Trypan blue–positive) 
after a single day and were not plated. Data 
in B and C are mean ± SD.
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Mcl1 haploinsufficiency protects mice from Myc-induced AML. (A) 
Kaplan-Meier survival analyses of mice transplanted with Myc or MIB. 
Congenic Mcl1fl/WT or Mcl1fl/null mice were used as bone marrow donors 
as indicated. Note the differences in time scale between the graphs. 
(B) Mcl1fl/null cells failed to support transformation by Myc. GFP+ cells 
in Mcl1fl/WT versus Mcl1fl/null recipients were determined by FACS 
before transplantation in bone marrow, at 3 weeks after transplanta-
tion in peripheral blood (PB), and at 6 weeks after transplantation in 
bone marrow. FCS, forward scatter. Numbers denote the percentage 
of events falling within the respective gate. Data are mean ± SD. (C) 
Mx1-Cre–mediated deletion of 1 Mcl1 allele from established AML 
cells significantly prolonged the survival of secondary recipients. Leu-
kemia cells from primary recipients of Mx1-CreMcl1fl/WT bone marrow 
transduced with Myc or MIB were transplanted into secondary recipi-
ents treated with pIpC or PBS. (D) PCR amplification of the 390-bp 
Mcl1fl and 340-bp Mcl1WT alleles from transplanted mice. Lane 1, Myc 
Mcl1fl/WT primary transplant; lane 2, MIB Mcl1fl/WT primary transplant; 
lane 3, Myc Mcl1fl/WT secondary transplant after pIpC treatment; lane 4, 
MIB Mcl1fl/WT secondary transplant after pIpC treatment; lane 5, MIB 
Mcl1fl/WT secondary transplant after pIpC treatment (spleen cells); lane 6, 
B6 129 Mcl1fl/WT pIpC-treated spleen cells; lane 7, B6 129 Mcl1fl/WT 
untreated control; lane 8, C57B6 WT control.
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Pharmacologic suppression of Mcl1 expression 
inhibits growth of murine and human AML cells. (A) 
Western blot of Mcl1 protein levels in lysates pre-
pared from MSCV-Myc AML cells treated in liquid 
culture for the indicated times with flavopiridol. NT, 
nontreated cells at 6 hours. Mouse embryonic fibro-
blasts were used as protein control. Ratio of Mcl1 
to actin protein levels, quantified by densitometry, 
are shown below. (B) Dose-dependent flavopiridol 
suppression of MSCV-Myc cytokine-independent 
methylcellulose colony growth. At flavopiridol doses 
less than 1 μM, growth of normal cytokine-depen-
dent bone marrow progenitors was not affected 
(not shown). (C) Survival of mice secondarily trans-
planted with MSCV-Myc AML cells was significantly 
prolonged by flavopiridol treatment. (D) MTT assay 
measurement of primary human AML cell growth in 
the presence of flavopiridol. Results from 4 separate 
patient samples, plated in triplicate, are shown. Data 
in B and D are mean ± SD.
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patients,  and RNA was prepared  from unfractionated  snap-frozen 
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Mcl1fl PCR were 5′-CTGAGAGTTGTACCGGACAA-3′ and 5′-GCAGTA-
CAGGTTCAAGCCGATG-3′.
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